Update on Japan progress, page-2

If anyone speaks Japanese and has an account, please feel free to view the whole article lol

"Australia Cynata Company, Phase I Patient Registration of Common iPS Cell-Derived Mesenchymal Stem Cells Started
Talk with the FDA for implementation of clinical trials in the United States

Australian Cynata Therapeutics company Ross Macdonald CEO and Kilian Kelly vice president who came to Japan for the general meeting of the 16th Japan Regenerative Medical Association which had been held in Sendai City, Miyagi prefecture until March 9, 2017, In response to Phase I of other iPS-derived mesenchymal stem cells (MSC) targeting graft-versus-host disease (GVHD), it was revealed that patient registration began at some implementation facilities. It is the first prospect in the world as a transplant of cells differentiated from other iPS cells (related article)."

第16回日本再生医療学会総会

豪Cynata社、他家iPS細胞由来間葉系幹細胞のフェーズIの患者登録開始
米国でも臨床試験の実施に向けFDAと協議へ
(2017.03.13 00:10)
久保田文

　2017年3月9日まで宮城県仙台市で開催されていた第16回日本再生医療学会総会のために来日したオーストラリアCynata Therapeutics社のRoss Macdonald CEOとKilian Kelly副社長が同日、本誌などの取材に応じ、移植片対宿主病（GVHD）を対象とした他家iPS由来間葉系幹細胞（MSC）のフェーズIについて、一部実施施設で患者登録が始まったことを明らかにした。他家iPS細胞から分化させた細胞の移植として、世界で初となる見込み（関連記事）。

https://bio.nikkeibp.co.jp/atcl/news/p1/17/03/11/02434/